The purpose of the NIMH Psychoactive Drug Screening Program is to provide pharmacological and functional screening of novel synthetic compounds and natural products for potential use as PET (positron emission tomography) ligands for functional brain imaging, research tools or probes for basic and clinical research, and therapeutic agents for mental disorders. The objectives of the contract are to receive and test coded samples (synthetic compounds, small molecules, gene products, and natural product extracts) in broad-based human and rodent CNS (central nervous system) receptor and enzyme binding assays, to test active samples in secondary functional assays, and to provide an electronic data file for each of the screened compounds. Approximately 60% of these samples are to be tested in human recombinant receptor assays. Samples for screening can include, but are not limited to, novel chemical entities, structural analogs of lead compounds, genes or gene products, small molecules, enzyme inhibitors, and natural products. It is anticipated that NIMH- approved and coded samples will be submitted from NIH- or federally- funded research programs and other academic research laboratories. It is expected that the screening information derived from this program will provide individual investigators with conceptual or structural leads for the design and/or development of new chemical entities, small molecules, gene products, tissue- or cell-specific drug delivery systems, therapeutic entities, or PET/SPECT ligands for human brain imaging.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research and Development Contracts (N01)
Project #
N01MH080005-005
Application #
6153931
Study Section
Project Start
1998-09-30
Project End
2001-09-29
Budget Start
1999-09-16
Budget End
2000-09-29
Support Year
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Madras, Bertha K; Fahey, Michele A; Goulet, Martin et al. (2006) Dopamine transporter (DAT) inhibitors alleviate specific parkinsonian deficits in monkeys: association with DAT occupancy in vivo. J Pharmacol Exp Ther 319:570-85
Kung, Mei-Ping; Choi, Seok-Rye; Hou, Catherine et al. (2004) Selective binding of 2-[125I]iodo-nisoxetine to norepinephrine transporters in the brain. Nucl Med Biol 31:533-41
Madras, Bertha K; Fahey, Michele A; Miller, Gregory M et al. (2003) Non-amine-based dopamine transporter (reuptake) inhibitors retain properties of amine-based progenitors. Eur J Pharmacol 479:41-51
Huang, Y; Kegeles, L S; Bae, S et al. (2001) Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands. Bioorg Med Chem Lett 11:1375-7
Rauser, L; Savage, J E; Meltzer, H Y et al. (2001) Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther 299:83-9
Choi, S R; Hou, C; Oya, S et al. (2000) Selective in vitro and in vivo binding of [(125)I]ADAM to serotonin transporters in rat brain. Synapse 38:403-12